The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
1975: Indian geneticist Archana Sharma received the Shanti Swarup Bhatnagar Prize, the first female recipient in the Biological Sciences category. 1975: Female officers of the British Geological Survey no longer had to resign upon getting married. 1975: Chien-Shiung Wu became the first female president of the American Physical Society. 1976: Filipino-American microbiologist Roseli Ocampo-Friedmann traveled to the Antarctic with Imre Friedmann and discovered micro-organisms living within the porous rock of the Ross Desert. These organisms – cryptoendoliths – were observed surviving extremely low temperatures and humidity, assisting scientific research into the possibility of life on Mars. 1976: Margaret Burbidge was named the first female president of the American Astronomical Society. 1977: American medical physicist Rosalyn Yalow received the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones" along with Roger Guillemin and Andrew V. Schally who received it "for their discoveries concerning the peptide hormone production of the brain". 1977: Austrian naturalist, artist and author Joy Adamson was awarded the Austrian Cross of Honour for Science and Art. Her book, Born Free, an international bestseller, describes her experiences raising a lion cub named Elsa. It was made into an Academy Award-winning film of the same name. 1977: The Association for Women Geoscientists was founded.
In enzymology, a 3-hydroxyisobutyrate dehydrogenase (EC 1.1.1.31) also known as β-hydroxyisobutyrate dehydrogenase or 3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH) is an enzyme that in humans is encoded by the HIBADH gene. 3-Hydroxyisobutyrate dehydrogenase catalyzes the chemical reaction:
Circulatory system: pumping and channeling blood to and from the body and lungs with heart, blood, blood vessels Digestive system: digestion and processing food with salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestines, rectum, anus Endocrine system: communication within the body using hormones made by endocrine glands such as the hypothalamus, pituitary gland, pineal gland, thyroid, parathyroid glands, adrenal glands Immune system: the system that fights off disease; composed of leukocytes, tonsils, adenoids, thymus, spleen Integumentary system: skin, hair, nails Lymphatic system: structures involved in the transfer of lymph between tissues and the blood stream, the lymph and the nodes and vessels that transport it Musculoskeletal system: muscles provide movement and a skeleton provides structural support and protection with bones, cartilage, ligaments, tendons Nervous system: collecting, transferring and processing information with brain, spinal cord, nerves Reproductive system: the sex organs; in the female; ovaries, fallopian tubes, uterus, vagina, mammary glands, and in the male; testicles, vas deferens, seminal vesicles, prostate, penis Respiratory system: the organs used for breathing, the pharynx, larynx, trachea, bronchi, lungs, diaphragm Urinary system: kidneys, ureters, bladder, urethra involved in fluid balance, electrolyte balance, and excretion of urine
== Taxonomic distribution and evolutionary advantages == Action potentials are found throughout multicellular organisms, including plants, invertebrates such as insects, and vertebrates such as reptiles and mammals. Sponges seem to be the main phylum of multicellular eukaryotes that does not transmit action potentials, although some studies have suggested that these organisms have a form of electrical signaling, too. The resting potential, as well as the size and duration of the action potential, have not varied much with evolution, although the conduction velocity does vary dramatically with axonal diameter and myelination.
Sources: en.wikipedia.org
Most charts or tables indicate the type of friction factor, or at least provide the formula for the friction factor with laminar flow. If the formula for laminar flow is f = 16/Re, it is the Fanning factor f, and if the formula for laminar flow is fD = 64/Re, it is the Darcy–Weisbach factor fD. Which friction factor is plotted in a Moody diagram may be determined by inspection if the publisher did not include the formula described above:
=== Indigenous peoples === The first inhabitants of North America are generally hypothesized to have migrated from Siberia by way of the Bering land bridge and arrived at least 14,000 years ago. The Paleo-Indian archaeological sites at Old Crow Flats and Bluefish Caves are two of the oldest sites of human habitation in Canada. The characteristics of Indigenous societies included permanent settlements, agriculture, complex societal hierarchies, and trading networks. Some of these cultures had collapsed by the time European explorers arrived in the late 15th and early 16th centuries and have only been discovered through archaeological investigations. Indigenous peoples in present-day Canada include the First Nations, Inuit, and Métis, the last being of mixed descent who originated in the mid-17th century when First Nations people married European settlers and their offspring subsequently developed their own identity. The Indigenous population at the time of the first European settlements is estimated to have been between 200,000 and two million, with a figure of 500,000 accepted by Canada's Royal Commission on Aboriginal Peoples. As a consequence of European colonization, the Indigenous population declined by forty to eighty percent. The decline is attributed to several causes, including the transfer of European diseases, to which they had no natural immunity, conflicts over the fur trade, conflicts with the colonial authorities and settlers, and the loss of Indigenous lands to settlers and the subsequent collapse of several nations' self-sufficiency.
Experts in the United Kingdom have suggested that some psychoactive drugs that may be causing less harm to fewer users (although they are also used less frequently in the first place) are cannabis, psilocybin mushrooms, LSD, and MDMA; however, these drugs have risks and side effects of their own.
Sources: en.wikipedia.org
Collagen XXIII belongs to the transmembranous subfamily of collagens. Proteins which are included in this group present an amino-terminal cytoplasmic domain followed by a membrane-spanning hydrophobic domain and at least one extracellular triple-helical collagenous domain alternated with short non-collagenous domains. Collagens XIII, XVII, and XXV, and related proteins such as class A macrophage scavenger receptors, ectodysplasin A or the MARCO1 receptor, are also part of this group. An alternative name for this type of protein is MACITs (membrane-associated collagens with interrupted triple helices). Collagen XXIII shows structural homology with collagen XIII and collagen XXV . Apart from having the characteristic structure of transmembranous collagens, all three proteins present a high level of amino acid residue conservation in collagenous and non-collagenous domains. Collagens α1(XIII), α1(XXIII) and α1(XXV) display three collagenous domains (Col 1, Col 2, and Col 3) and four non-collagenous domains (NC1, which is also a transmembranous domain, NC2, NC3 and NC4). It has been reported that Col 1 domain of α1(XXIII) shows similarities with regions of both Col 1 and Col 2 domains of collagen types α1(XIII) and α1(XXV), whilst sequences of Col 2 and Col 3 domains of α1(XXIII) are related to the Col 3 domain of types α1(XIII)and α1(XXV). Short non-collagenous domains also exhibit similarities, especially in the NC1 and NC4 domains. Between 60 and 78% of the amino acid residues of these domains are identical in all three chains.
Corneal abrasion – a medical condition involving the loss of the surface epithelial layer of the eye's cornea as a result of trauma to the surface of the eye. Corneal dystrophy – a condition in which one or more parts of the cornea lose their normal clarity due to a buildup of cloudy material. Corneal ulcer – an inflammatory or infective condition of the cornea involving disruption of its epithelial layer with involvement of the corneal stroma. Corneal neovascularization – excessive ingrowth of blood vessels from the limbal vascular plexus into the cornea, caused by deprivation of oxygen from the air. Fuchs' dystrophy – cloudy morning vision. Keratitis – inflammation of the cornea. Keratoconus – a degenerative disease, the cornea thins and changes shape to be more like a cone. Corneal foreign body – a foreign object present in the cornea, one of the most common preventable occupational hazards.
=== Osteoarthritis risk === Variations in the COL2A1 gene may increase susceptibility to osteoarthritis in some individuals. These variations alter amino acids in the pro-alpha1(II) chain, potentially affecting collagen fiber integrity in joint cartilage and contributing to degenerative joint disease.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.